Welcome to our dedicated page for Intellia Therapeutics SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intellia Therapeutics, Inc. filings document the business, governance and capital structure of a Nasdaq-listed clinical-stage biopharmaceutical company developing CRISPR-based therapies. Its Form 8-K reports record quarterly financial results and business updates, clinical and regulatory disclosures for lonvo-z in hereditary angioedema, nex-z in ATTR amyloidosis, and related FDA communications.
The filing record also includes common stock financing disclosures, including an underwritten public offering and amendments to an at-the-market sales program. Proxy materials describe annual meeting matters, executive compensation, equity awards and board governance, while bylaw amendments and other corporate filings address shareholder proposal procedures, forum provisions and registered common stock listed on The Nasdaq Global Market.
Intellia Therapeutics, Inc. (NTLA) reports that the U.S. FDA has accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema and granted Priority Review with a Prescription Drug User Fee Act target action date of March 10, 2027. FDA also indicated it is not currently planning to hold an advisory committee meeting on the application. The BLA is supported by a global Phase 3 HAELO trial of 80 patients, where a single 50 mg dose of lonvo-z achieved an 87% reduction in mean monthly attacks versus placebo and 62% of treated patients were attack-free and HAE-therapy-free over six months. All treatment-emergent adverse events in the lonvo-z arm were mild or moderate with no serious adverse events reported. Intellia highlights that, if approved, lonvo-z could become the first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
Intellia Therapeutics, Inc. (NTLA) entered into a senior secured Credit Agreement with OrbiMed-affiliated lenders providing a five-year credit facility of up to $400 million. An initial $75 million was drawn at closing, with additional tranches tied to regulatory, revenue and equity fundraising milestones, plus an uncommitted $100 million incremental option.
The facility matures on September 4, 2031. Loans bear monthly interest at the one-month SOFR (with a 3.00% floor) plus a 6.15% margin, implying a minimum annual rate of 9.15%, plus customary fees. Obligations are secured by first‑priority liens on substantially all company assets, including intellectual property, and are subject to mandatory prepayments from certain debt financings, asset sales and casualty proceeds.
Covenants include maintaining at least $50 million of liquidity in controlled accounts until FDA approval of the BLA for lonvoguran ziclumeran (lonvo‑z), and thereafter satisfying revenue, market capitalization or cash-balance tests. Negative covenants restrict additional debt, liens, M&A, asset sales, licensing and dividends, while permitting certain synthetic royalty transactions. Proceeds are for working capital and general corporate purposes.
Intellia Therapeutics, Inc. (NTLA) reported that President and CEO John M. Leonard sold shares of Common Stock in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On August 20, 2026, he sold 19,890 shares at a weighted average price of $12.60 per share, in multiple trades between $12.32 and $13.00. On August 21, 2026, he sold an additional 2,785 shares at $13.00 per share. The filing also notes 58,415 shares of common stock held indirectly by the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics, Inc. (symbol NTLA) received a notice that John M. Leonard intends to sell common stock under Rule 144. The planned sale covers 22,675 shares of common stock through UBS Financial Services Inc., with an aggregate market value of $293,641.25, listed on NASDAQ and noted with a proposed sale date of 08/20/2026.
The shares relate to earlier acquisitions from stock option exercises by the issuer, including 3,000 shares on 04/13/2021 and 19,675 shares on 02/09/2021, both for cash. UBS Financial Services Inc. signed as attorney-in-fact for John Leonard.
Intellia Therapeutics, Inc. (NTLA) reports that State Street Corporation has filed as an institutional holder of its common stock. State Street reports 9,234,987 shares beneficially owned, representing 6.8% of the outstanding common stock as of the reporting date. It has shared voting power over 8,907,136 shares and shared dispositive power over 9,234,987 shares, with no sole voting or dispositive power. The holding is reported on behalf of State Street and certain investment advisory subsidiaries, including SSGA Funds Management, Inc. and State Street Global Advisors entities.
Intellia Therapeutics reported second quarter 2026 results and major progress in its gene-editing pipeline. In the Phase 3 HAELO trial for hereditary angioedema, one-time treatment lonvo-z met its primary endpoint, reducing attacks by 87% versus placebo over weeks 5–28, with a mean monthly attack rate of 0.26 versus 2.10. Key secondary endpoints all reached statistical significance, including 62% of lonvo-z patients being attack- and therapy-free versus 11% on placebo. Safety findings showed only mild or moderate treatment emergent adverse events and no serious adverse events in the lonvo-z arm. Intellia plans a biologics license application to the FDA with expected acceptance in the second half of 2026 and a potential U.S. launch in the first half of 2027.
For its ATTR amyloidosis program, Intellia advanced Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nex-z and aims to complete MAGNITUDE-2 enrollment in the second half of 2026. A genomic analysis linked higher liver transaminase elevations to one human leukocyte antigen allele, guiding HLA genotyping in ongoing studies. Financially, collaboration revenue was $7,659 thousand in the quarter, research and development expenses were $82,595 thousand, general and administrative expenses were $37,824 thousand, and net loss was $106,634 thousand. Cash, cash equivalents and marketable securities totaled $628,354 thousand at June 30, 2026, which Intellia expects will fund operations at least into 2028.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported a mandatory sell-to-cover sale of 8,111 shares of common stock on July 22, 2026 to satisfy tax withholding from RSU vesting. The shares were sold at a weighted average price of $11.25, within a range from $11.25 to $11.28, leaving 148,175 shares directly owned.
Intellia Therapeutics, Inc. executive Michael P. Dube, VP and Chief Accounting Officer, reported a sale of 2,641 shares of common stock on July 1, 2026 at a weighted average price of $16.78 per share.
According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units (RSUs) on the same date, and is explicitly described as not a voluntary trade. After this tax-related sale, Dube held 66,886 shares of Intellia common stock directly.
Intellia Therapeutics EVP and CFO Edward J. Dulac III sold 4,677 shares of Common Stock in an open-market transaction. The sale took place on July 2, 2026 at a price of $18.00 per share and was executed under a pre-established Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, Dulac directly holds 156,286 shares of Intellia Therapeutics common stock, indicating he retains a substantial equity stake despite this planned sale.